Could cilostazol beat aspirin at preventing strokes?
NCT ID NCT07180472
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study compares cilostazol, aspirin, and clopidogrel in 632 people who recently had a stroke due to cerebral small vessel disease. The goal is to see if cilostazol is better at preventing another stroke and slowing disease progression, with fewer bleeding risks. Participants will take one of the three drugs and be followed for outcomes like new strokes, cognitive decline, and disability.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Cilostazol
- What this could lead to
- If it works, this could provide a safer and more effective option to prevent recurrent strokes and slow cognitive decline in people with cerebral small vessel disease.
- What could go wrong
- This is a Phase 4 trial, but results may not apply to all patients. Cilostazol may not prove superior to existing drugs, and bleeding risks remain possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CEREBRAL SMALL VESSEL DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can brain scans predict the progression of silent stroke damage?
- Brain scan and blood test study aims to predict stroke recovery
- Could Low-Field MRI revolutionize brain disease detection?
- Eye scans may predict brain disease in massive new study
- Brain zaps help stroke survivors walk better?
- Could a diabetes drug shield your brain from stroke and dementia?